Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans

References

• Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. 2020. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 29(2):135–141.
   PubMed Web of Science ®Google Scholar
• Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D. 2021. Investigation into MAO B-mediated formation of CC112273, a major circulating metabolite of ozanimod, in humans and preclinical species: stereospecific oxidative deamination of (S)-enantiomer of indaneamine (RP101075) by MAO B. Drug Metab Dispos. 49(8):601–609.
   PubMed Web of Science ®Google Scholar
• Bergman A, Carvajal-Gonzalez S, Tarabar S, Saxena AR, Esler WP, Amin NB. 2020. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF-05221304): a three-part randomized phase 1 study. Clin Pharmacol Drug Dev. 9(4):514–526.
   PubMed Web of Science ®Google Scholar
• Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, et al. 2021. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 27(10):1836–1848.
   PubMed Web of Science ®Google Scholar
• Eng H, Bi YA, West MA, Ryu S, Yamaguchi E, Kosa RE, Tess DA, Griffith DA, Litchfield J, Kalgutkar AS, et al. 2021. Organic anion-transporting polypeptide 1B1/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: in vitro-in vivo evaluation in cynomolgus monkey. J Pharmacol Exp Ther. 377(1):169–180.
   PubMed Web of Science ®Google Scholar
• El-Kattan AF, Varma MVS. 2018. Navigating transporter sciences in pharmacokinetics characterization using the extended clearance classification system. Drug Metab Dispos. 46(5):729–739.
   PubMed Web of Science ®Google Scholar
• Esler WP, Bence KK. 2019. Metabolic targets in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 8(2):247–267.
   PubMed Web of Science ®Google Scholar
• Griffith DA, Kung DW, Esler WP, Amor PA, Bagley SW, Beysen C, Carvajal-Gonzalez S, Doran SD, Limberakis C, Mathiowetz AM, McPherson K, Price DA, et al. 2014. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem. 57(24):10512–10526.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. 1981. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 29(3):408–413.
   PubMed Web of Science ®Google Scholar
• Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha A, Westlin WF, Kapeller R, et al. 2016. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci USA. 113(13):E1796–E1805.
   PubMed Web of Science ®Google Scholar
• Harwood HJ, Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, et al. 2003. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem. 278(39):37099–37111.
   PubMed Web of Science ®Google Scholar
• Huard K, Smith AC, Cappon G, Dow RL, Edmonds DJ, El-Kattan A, Esler WP, Fernando DP, Griffith DA, Kalgutkar AS, et al. 2020. Optimizing the benefit/risk of acetyl-CoA carboxylase inhibitors through liver targeting. J Med Chem. 63(19):10879–10896.
   PubMed Web of Science ®Google Scholar
• Kelly KL, Reagan WJ, Sonnenberg GE, Clasquin M, Hales K, Asano S, Amor PA, Carvajal-Gonzalez S, Shirai N, Matthews MD, et al. 2020. De novo lipogenesis is essential for platelet production in humans. Nat Metab. 2(10):1163–1178.
   PubMedGoogle Scholar
• Kim CW, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, Burgess SC, Li C, Ruddy M, Chakravarthy M, et al. 2017. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 26(3):309–406.
   Web of Science ®Google Scholar
• Kirby BJ, Lutz JD, Yue MS, Garrison KL, Qin AR, Ampaw L, Beysen C, Myers RP, Kearney BP, Mathias A. 2021. Organic anion transporting polypeptide inhibition dramatically increases plasma exposure but not pharmacodynamic effect nor inferred hepatic intracellular exposure of firsocostat. Clin Pharmacol Ther. 109(5):1334–1341.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, Benet LZ. 2007. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 81(2):194–204.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, et al. 2018. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 16(12):1983–1991.
   PubMed Web of Science ®Google Scholar
• Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, et al. 2018. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 155(5):1463–1473.
   PubMed Web of Science ®Google Scholar
• McGarry JD, Mannaerts GP, Foster DW. 1977. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 60(1):265–270.
   PubMed Web of Science ®Google Scholar
• Mori D, Kimoto E, Rago B, Kondo Y, King-Ahmad A, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, et al. 2020. Dose-dependent inhibition of OATP1B by rifampicin in healthy volunteers: comprehensive evaluation of candidate biomarkers and OATP1B probe drugs. Clin Pharmacol Ther. 107(4):1004–1013.
   PubMed Web of Science ®Google Scholar
• Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. 2020. The race to bash NASH: emerging targets and drug development in a complex liver disease. J Med Chem. 63(10):5031–5073.
   PubMed Web of Science ®Google Scholar
• Roth M, Obaidat A, Hagenbuch B. 2012. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 165(5):1260–1287.
   PubMed Web of Science ®Google Scholar
• Saggerson D. 2008. Malonyl-CoA, a key signaling molecule in mammalian cells. Annu Rev Nutr. 28:253–272.
   PubMed Web of Science ®Google Scholar
• Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, et al. 2006. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 116(3):817–824.
   PubMed Web of Science ®Google Scholar
• Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, et al. 2018. A decade in the MIST: Learnings from investigations of drug metabolites in drug development under the “metabolites in safety testing” regulatory guidance. Drug Metab Dispos. 46(6):865–878.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. 2013. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 34(1):45–78.
   PubMed Web of Science ®Google Scholar
• Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJ, Jr, Kelley H, Kapeller R, Schmalbach T, Westlin WF. 2017. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology. 66(2):324–334.
   PubMed Web of Science ®Google Scholar
• Tess DA, Eng H, Kalgutkar AS, Litchfield J, Edmonds DJ, Griffith DA, Varma MVS. 2020. Predicting the human hepatic clearance of acidic and zwitterionic drugs. J Med Chem. 63(20):11831–11844.
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Kalow W, Inaba T. 1991. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol. 31(6):655–660.
   PubMed Web of Science ®Google Scholar
• Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM. 2017. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin Pharmacol Ther. 101(3):406–415.
   PubMed Web of Science ®Google Scholar
• Waite M, Wakil SJ. 1962. Studies on the mechanism of fatty acid synthesis. XII. Acetyl coenzyme A carboxylase. J Biol Chem. 237:2750–2757.
   PubMed Web of Science ®Google Scholar